Vikki Barrett

Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT_1B/1D receptor partial agonist, 311C90 (zolmitriptan)

Graeme R. Martin, Alan D. Robertson, Sara MacLennan et al. · British Journal of Pharmacology · 1997 · 101 citations · Full text

Pharmacotherapy, Experimental Pharmacology, Molecular Pharmacology +20

Comparative analysis of two types of 5-hydroxytryptamine receptor mediating vasorelaxation: differential classification using tryptamines

Graeme R. Martin, P. Leff, D. Cambridge et al. · Naunyn-Schmiedeberg s Archives of Pharmacology · 1987 · 77 citations

5-Hydroxytryptamine Receptor, Functional Selectivity, Medicine +8

Prolonged Scar-in-a-Jar: an in vitro screening tool for anti-fibrotic therapies using biomarkers of extracellular matrix synthesis

Sarah Rank Rønnow, Rand Qais Dabbagh, Federica Genovese et al. · Respiratory Research · 2020 · 42 citations · Full text

Discovery of 4-[3-(<i>trans</i>-3-Dimethylaminocyclobutyl)-1<i>H</i>-indol-5-ylmethyl]- (4<i>S</i>)-oxazolidin-2-one (4991W93), a 5HT_1B/1DReceptor Partial Agonist and a Potent Inhibitor of Electrically Induced Plasma Extravasation

Karamjit S. Jandu, Vikki Barrett, Michael Brockwell et al. · Journal of Medicinal Chemistry · 2001 · 41 citations · Full text

Potent Inhibitor, Pharmacotherapy, Experimental Pharmacology +17

Pharmacological analysis of the interaction between Bay K 8644 and 5‐HT in rabbit aorta

Vikki Barrett, P. Leff, Graeme R. Martin et al. · British Journal of Pharmacology · 1986 · 19 citations · Full text

Molecular Pharmacology, Isolated Aorta Preparation, Cardiovascular Disease +15